|1.||Synold, Timothy W: 4 articles (09/2008 - 06/2008)|
|2.||Kozielski, Frank: 2 articles (06/2013 - 03/2013)|
|3.||Kaan, Hung Yi Kristal: 2 articles (06/2013 - 03/2013)|
|4.||Conlan, Maureen G: 2 articles (03/2012 - 12/2010)|
|5.||Tomillero, A: 2 articles (06/2010 - 07/2008)|
|6.||Moral, M A: 2 articles (06/2010 - 07/2008)|
|7.||Vasist, Lakshmi S: 2 articles (09/2008 - 06/2008)|
|8.||Seymour, Lesley: 2 articles (06/2008 - 06/2008)|
|9.||Wainman, Nancy: 2 articles (06/2008 - 06/2008)|
|10.||Hussain, Maha: 2 articles (03/2008 - 01/2006)|
|1.||Prostatic Neoplasms (Prostate Cancer)
09/01/2008 - "Ispinesib was inactive in this study of patients with androgen-independent, and largely docetaxelresistant, prostate cancer. "
09/01/2008 - "Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes."
01/01/2006 - "Hence, we believe that SB715992 could be a novel agent for the treatment of prostate cancer with greater success when combined with a non-toxic natural agent like genistein."
01/01/2006 - "Our major objective was a) to investigate the cell growth inhibitory effects of SB715992 on PC-3 human prostate cancer cell line, b) to investigate whether the growth inhibitory effects of SB715992 could be enhanced when combined with genistein, a naturally occurring isoflavone and, c) to determine gene expression profile to establish molecular mechanism of action of SB715992. "
01/01/2006 - "Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line."
|2.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
|3.||Osteosarcoma (Osteogenic Sarcoma)
08/01/2014 - "We applied this approach to ispinesib and YM155, drugs that have undergone clinical trials as anticancer agents, and uncovered mechanisms of action and identified genetic and epigenetic mechanisms likely to cause drug resistance in human cancer cells. "
06/18/2008 - "Ispinesib (SB-715992), a potent and selective inhibitor of KSP, is currently in phase II clinical trials for the treatment of multiple tumor types. "
03/14/2013 - "We report here their further optimization to produce extremely potent inhibitors of Eg5 (K(i)(app) < 10 nM) with broad-spectrum activity against cancer cell lines comparable to the Phase II drug candidates ispinesib and SB-743921. "
12/15/2010 - "The maximum tolerated and recommended phase II dose for ispinesib administered weekly × 3 every 28 days for children with solid tumors is 9 mg/m(2) /dose. "
09/28/2010 - "The data also suggest that targeting this novel site could be a productive strategy for eluding Ispinesib-resistant tumors. "
|5.||Breast Neoplasms (Breast Cancer)
09/28/2010 - "This series also binds in the presence of Ispinesib, a known anticancer KSP inhibitor in phase I/II clinical trials for breast cancer. "
01/15/2010 - "Clinical studies of ispinesib have shown a 9% response rate in patients with locally advanced or metastatic breast cancer and a favorable safety profile without significant neurotoxicities, gastrointestinal toxicities, or hair loss. "
01/15/2010 - "To better understand the potential of ispinesib in the treatment of breast cancer, we explored the activity of ispinesib alone and in combination with several therapies approved for the treatment of breast cancer. "
03/01/2012 - "Patients with locally advanced or metastatic breast cancer who had received only prior neoadjuvant or adjuvant chemotherapy were treated with escalating doses of ispinesib administered as a 1-h infusion on days 1 and 15 every 28 days until toxicity or progression of disease. "
01/15/2010 - "We measured the ispinesib sensitivity and pharmacodynamic response of breast cancer cell lines representative of various subtypes in vitro and as xenografts in vivo and tested the ability of ispinesib to enhance the antitumor activity of approved therapies. "
|3.||N- propyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (PPTP)
|7.||4- ((4- Fluoro- 2- methyl- 1H- indol- 5- yl)oxy)- 6- methoxy- 7- (3- (pyrrolidin- 1- yl)propoxy)quinazoline (AZD2171)
|8.||ixabepilone (BMS 247550)
|1.||Heterologous Transplantation (Xenotransplantation)